Immunomodulatory effects of sorafenib on peripheral immune effector cells in ... - UroToday PDF Print
UroToday
Tyrosine kinase inhibitors (TKI) such as sorafenib have substantially improved the prognosis of metastatic renal cell carcinoma (mRCC) patients,

...

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.